Advances in radiofrequency ablation for pancreatic cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: locally advanced or unresectable disease
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Additionally, RFA-induced tumor antigen release and modulation of the tumor microenvironment suggest a potential synergistic role with immunotherapy. Despite its promise, the widespread adoption of EUS-RFA is limited by a lack of large-scale randomized controlled trials and standardized treatment protocols.
Radiofrequency ablation (RFA), particularly endoscopic ultrasound-guided RFA (EUS-RFA), has emerged as a promising minimally invasive approach for the treatment of pancreatic cancer, especially in pat
APA
Peng SY, Li ZY, Cai HQ (2026). Advances in radiofrequency ablation for pancreatic cancer.. World journal of gastrointestinal oncology, 18(1), 113764. https://doi.org/10.4251/wjgo.v18.i1.113764
MLA
Peng SY, et al.. "Advances in radiofrequency ablation for pancreatic cancer.." World journal of gastrointestinal oncology, vol. 18, no. 1, 2026, pp. 113764.
PMID
41607743 ↗
Abstract 한글 요약
Radiofrequency ablation (RFA), particularly endoscopic ultrasound-guided RFA (EUS-RFA), has emerged as a promising minimally invasive approach for the treatment of pancreatic cancer, especially in patients with locally advanced or unresectable disease. This review outlines recent technological developments in EUS-RFA, including innovations in energy delivery systems, probe design, and real-time thermal monitoring, which have improved the precision and safety of the procedure. Clinical studies combining EUS-RFA with chemotherapy have demonstrated encouraging outcomes, with improvements in overall survival, progression-free survival, tumor necrosis, and symptom control compared to chemotherapy alone. Additionally, RFA-induced tumor antigen release and modulation of the tumor microenvironment suggest a potential synergistic role with immunotherapy. Despite its promise, the widespread adoption of EUS-RFA is limited by a lack of large-scale randomized controlled trials and standardized treatment protocols.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- The tumor microenvironment as a key regulator of radiotherapy response.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.